Page 126 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Zercepac + pyrotinib versus pertuzumab in HER2+ BC
®

Table 6. Comparison of efficacy and adverse reactions between TCbHP and TCbHPy regimens
Regimen TCbHP (n=29) TCbHPy (n=8) χ 2 p
Efficacy (n) 4.06 0.25
tpCR 16 3
bpCR 5 1
apCR 1 2
PR 7 2
Ki-67 variation (n) 0.80 0.67
No reduction 2 0
Reduction (<15%) 2 1
Significant reduction (>15%) 25 7
MP grade (n) 6.91 0.07
Grade 2 2 0
Grade 3 2 0
Grade 4 3 4
Grade 5 22 4
Cardiac adverse events (n [%])
ST-segment changes 1 (3.45%) 1 (12.50%) 0.01 0.91
Clockwise or counter-clockwise rotation 3 (10.34%) 0 (0%) 0.05 0.83
Premature atrial or ventricular contractions 0 (0%) 2 (25.00%) 3.55 0.06
Sinus arrhythmia (a) 5 (17.24%) 0 (0%) 0.46 0.50
Conduction block (b) 0 (0%) 0 (0%) NA 1
Low QRS voltage 1 (3.45%) 0 (0%) <0.001 1
Left axis deviation 0 (0%) 1 (12.50%) 0.49 0.48
Left ventricular hypertrophy 1 (3.45%) 0 (0%) <0.001 1
Adverse reactions (n [%])
Alopecia (hair loss) 25 (86.21%) 8 (100%) 0.22 0.64
Nausea 17 (58.62%) 3 (37.50%) 0.44 0.51
Diarrhea 1 (3.45%) 8 (100%) 26.73 < 0.001
Abdominal pain 4 (13.80%) 0 (0%) 0.22 0.64
Low white blood cell count 5 (17.24%) 2 (25.00%) <0.001 1
Low hemoglobin 2 (6.90%) 0 (0%) <0.001 1
Low platelet count 5 (17.24%) 0 (0%) 0.46 0.50
Abnormal liver function 9 (31.03%) 1 (12.50%) 0.35 0.55
Arthralgia (joint pain) 3 (10.34%) 0 (0%) 0.05 0.83
Anemia 14 (48.28%) 3 (37.50%) 0.02 0.89
Abbreviations: apCR: Pathological complete remission of axillary lymph nodes; bpCR: Pathological complete remission of primary breast lesions;
MP: Miller–Payne; NA: Not available; PR: Partial pathological response; TCbHP: Docetaxel + carboplatin + trastuzumab + pertuzumab;
TCbHPy: Docetaxel + carboplatin + trastuzumab + pyrotinib; tpCR: Total pathological complete response.

This may be due to the small sample size and dose tpCR between the TCbHPy and TCbHP groups showed
reductions caused by adverse effects. Although the tpCR no significant differences (p=0.25). Similarly, MP grading
rate in the trastuzumab + Py group was lower than that in showed no statistically significant difference (p=0.07).
the trastuzumab + pertuzumab group, statistical analyses In terms of adverse reactions, there were no statistically
of partial pathological response, pathological complete significant differences between the two groups in hair
remission of primary breast lesions (bpCR), pathological loss, nausea, vomiting, fatigue, diarrhea, loss of appetite,
complete remission of axillary lymph nodes (apCR), and or cardiovascular adverse events (such as pre-mature

Volume 9 Issue 3 (2025) 118 doi: 10.36922/EJMO025100044